JP2021519072A5 - - Google Patents

Info

Publication number
JP2021519072A5
JP2021519072A5 JP2020551549A JP2020551549A JP2021519072A5 JP 2021519072 A5 JP2021519072 A5 JP 2021519072A5 JP 2020551549 A JP2020551549 A JP 2020551549A JP 2020551549 A JP2020551549 A JP 2020551549A JP 2021519072 A5 JP2021519072 A5 JP 2021519072A5
Authority
JP
Japan
Prior art keywords
gnc
cancer cells
guidance
binding domain
navigation control
Prior art date
Application number
JP2020551549A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021519072A (ja
JPWO2019191120A5 (https=
JP7573441B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/024105 external-priority patent/WO2019191120A1/en
Publication of JP2021519072A publication Critical patent/JP2021519072A/ja
Publication of JPWO2019191120A5 publication Critical patent/JPWO2019191120A5/ja
Publication of JP2021519072A5 publication Critical patent/JP2021519072A5/ja
Priority to JP2024180215A priority Critical patent/JP7781243B2/ja
Application granted granted Critical
Publication of JP7573441B2 publication Critical patent/JP7573441B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020551549A 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 Active JP7573441B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024180215A JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862648888P 2018-03-27 2018-03-27
US201862648880P 2018-03-27 2018-03-27
US62/648,888 2018-03-27
US62/648,880 2018-03-27
PCT/US2019/024105 WO2019191120A1 (en) 2018-03-27 2019-03-26 Guidance and navigation control proteins and method of making and using thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024180215A Division JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Publications (4)

Publication Number Publication Date
JP2021519072A JP2021519072A (ja) 2021-08-10
JPWO2019191120A5 JPWO2019191120A5 (https=) 2022-05-11
JP2021519072A5 true JP2021519072A5 (https=) 2022-05-11
JP7573441B2 JP7573441B2 (ja) 2024-10-25

Family

ID=68060498

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020551503A Pending JP2021519289A (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2020551549A Active JP7573441B2 (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2023216572A Pending JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2024180215A Active JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2020551503A Pending JP2021519289A (ja) 2018-03-27 2019-03-26 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023216572A Pending JP2024045111A (ja) 2018-03-27 2023-12-22 ガイダンス及びナビゲーションコントロール蛋白質の生産及び使用方法
JP2024180215A Active JP7781243B2 (ja) 2018-03-27 2024-10-15 ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法

Country Status (11)

Country Link
US (2) US20210008113A1 (https=)
EP (2) EP3774918A4 (https=)
JP (4) JP2021519289A (https=)
KR (2) KR20200139130A (https=)
CN (5) CN111527108A (https=)
AU (4) AU2019243453B2 (https=)
CA (2) CA3094997A1 (https=)
IL (4) IL271348B2 (https=)
SG (2) SG11202008470WA (https=)
TW (2) TW202003037A (https=)
WO (2) WO2019191125A1 (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250376531A9 (en) * 2017-06-25 2025-12-11 Systimmune, Inc. Anti-4-1bb antibodies and methods of making and using thereof
EP3645738A4 (en) * 2017-06-25 2021-08-18 Systimmune, Inc. ANTI-PD-L1 ANTIBODIES AND METHOD FOR MANUFACTURING AND USING THEREOF
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
WO2019005636A2 (en) * 2017-06-25 2019-01-03 Systimmune, Inc. ANTI-ROR1 ANTIBODIES AND METHODS OF PREPARATION AND USE
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins
CN114502203B (zh) * 2019-11-06 2024-07-19 成都百利多特生物药业有限责任公司 制导和导航控制蛋白及其制备和使用方法
EP4077374A4 (en) * 2019-12-20 2023-12-27 Kisoji Biotechnology Inc. POLYPEPTIDES, PROTEIN COMPLEXES AND METHODS FOR PRODUCING THE SAME
WO2021178253A1 (en) * 2020-03-03 2021-09-10 Systimmune, Inc. Anti-cd19 antibodies and methods of using and making thereof
TWI874613B (zh) * 2020-03-17 2025-03-01 美商西雅圖免疫公司 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
FI4284512T3 (fi) 2021-01-28 2025-05-22 Regeneron Pharma Koostumuksia ja menetelmiä sytokiinien vapautumisoireyhtymän hoitamiseksi
AU2022283436A1 (en) * 2021-05-28 2023-11-30 Dana-Farber Cancer Institute, Inc. Multi-specific antibody constructs against the muc1-c/extracellular domain ( muc1-c/ecd)
TW202334223A (zh) 2021-11-11 2023-09-01 美商再生元醫藥公司 Ｃｄ２０－ｐｄ１結合分子及其使用方法
CN119546329A (zh) 2022-04-11 2025-02-28 瑞泽恩制药公司 用于通用肿瘤细胞杀伤的组合物和方法
JP2025512953A (ja) * 2022-04-11 2025-04-22 アストラゼネカ・アクチエボラーグ Ｔ細胞結合タンパク質
KR20250151441A (ko) 2023-02-17 2025-10-21 리제너론 파마슈티칼스 인코포레이티드 Cd3/taa 이중특이적 항체에 대해 반응성인 유도된 nk 세포

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1354600A1 (en) * 2002-04-19 2003-10-22 Affimed Therapeutics AG Antibody combination useful for tumor therapy
JP6190723B2 (ja) * 2010-12-01 2017-08-30 アルダーバイオ ホールディングス エルエルシー 抗ｎｇｆ組成物およびその使用
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
EP2930188A1 (en) 2014-04-13 2015-10-14 Affimed Therapeutics AG Trifunctional antigen-binding molecule
US10519248B2 (en) * 2014-07-25 2019-12-31 Memorial Sloan Kettering Cancer Center Bispecific HER2 and CD3 binding molecules
WO2016019969A1 (en) * 2014-08-08 2016-02-11 Ludwig-Maximilians-Universität München Subcutaneously administered bispecific antibodies for use in the treatment of cancer
EP2990416B1 (en) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
WO2016115274A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
EP3288975A1 (en) * 2015-04-29 2018-03-07 Institute for Research in Biomedicine Ultra-potent neutralization of cytokines by multispecific antibodies and uses thereof
WO2017011342A1 (en) * 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
EP3156417A1 (en) * 2015-10-13 2017-04-19 Affimed GmbH Multivalent fv antibodies
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
IL262241B2 (en) * 2016-04-13 2024-05-01 Sanofi Sa Trispecific and/or trivalent binding proteins with a crossover dual variable domain arm and a traditional antibody fab arm, pharmaceutical composition comprising said binding proteins and their uses in preventing and/or treating cancer or inflammatory diseases
JP7038353B2 (ja) * 2016-04-13 2022-03-18 ヴィヴィア バイオテック，エス．エル エクスビボのｂｉｔｅ活性化ｔ細胞
US10188749B2 (en) * 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
IL262365B2 (en) 2016-04-15 2024-11-01 Alpine Immune Sciences Inc Immunomodulatory proteins ICOS ligand variants and uses thereof
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
CN106589129B (zh) 2016-12-30 2021-03-05 上海近岸生物科技有限公司 一种结合cd19、cd3和cd28的三功能分子及其应用
TWI828625B (zh) * 2017-06-25 2024-01-11 美商西雅圖免疫公司 引導及導航控制蛋白質以及彼之製造及使用方法
SG11201912865VA (en) * 2017-06-25 2020-01-30 Systimmune Inc Multi-specific antibodies and methods of making and using thereof
CN116948035A (zh) * 2017-06-25 2023-10-27 西雅图免疫公司 多特异性抗体及其制备和使用方法
US20210008113A1 (en) * 2018-03-27 2021-01-14 Systimmune, Inc. Methods of making and using guidance and navigation control proteins

Similar Documents

Publication Publication Date Title
JP2021519072A5 (https=)
JP2020529864A5 (https=)
JPWO2019191120A5 (https=)
AU2015303135B2 (en) SIRP-alpha immunoglobulin fusion proteins
ES2850325T3 (es) Anticuerpos biespecíficos contra CD3epsilon y ROR1
JP2020530306A5 (https=)
JP2020530777A5 (https=)
JP2018525033A5 (https=)
JP2024023228A5 (https=)
Urbanska et al. Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
JPWO2020113164A5 (https=)
JPWO2019005637A5 (https=)
CN115698088A (zh) 免疫细胞衔接器多特异性结合蛋白及其制备和应用
CN115066274A (zh) 三价结合分子
RU2020116541A (ru) Слитые белки однодоменное антитело-цитозиндезаминаза
JP2020535796A5 (https=)
CA3043652A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
CN111699201A (zh) 抗pd-1/抗her2天然抗体结构的异源二聚双特异性抗体及其制备方法
JPWO2020146221A5 (https=)
WO2022148410A1 (zh) 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备
JP2020536518A5 (https=)
US20230002488A1 (en) Guidance and navigation control proteins and method of making and using thereof
CN114539402A (zh) 靶向Claudin18.2的抗体及其用途
JP2021501575A (ja) 二重特異性抗体並びにその製造方法及び使用方法